Scarica l'app Stockscreener
5.43
6.26%
0.32
Dopo l'orario di chiusura:
5.45
0.02
+0.37%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VIR Giù?
Forum
Previsione
Vir Biotechnology Inc Borsa (VIR) Ultime notizie
Long Term Trading Analysis for (VIR) - news.stocktradersdaily.com
Transcript : Vir Biotechnology, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 04 - MarketScreener
(VIR) Trading Advice - news.stocktradersdaily.com
Vir Biotechnology director Janet Napolitano sells $16,148 in stock - Investing.com Australia
Vir Biotechnology director Janet Napolitano sells $16,148 in stock By Investing.com - Investing.com Nigeria
Vir Biotechnology Holds 2025 Annual Stockholder Meeting - TipRanks
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - BioSpace
Vir Biotechnology to Participate in the Goldman Sachs 46th Annua - GuruFocus
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 | VIR Stock News - GuruFocus
Vir Biotech at TD Cowen’s Summit: Strategic Focus on HDV and Oncology - Investing.com
Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga
Vir Biotechnology (VIR) Maintains 'Buy' Rating with $14 Price Ta - GuruFocus
Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit - BioSpace
Vir Biotechnology stock target cut to $15 by H.C. Wainwright - Investing.com Australia
Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit | VIR Stock News - GuruFocus
Vir Biotechnology’s SWOT analysis: HDV treatment potential lifts stock outlook - Investing.com Australia
Vir Biotechnology (VIR) Price Target Slashed Amid Clinical Trial Results | VIR Stock News - GuruFocus
How Vir CEO Marianne De Backer Is Rebuilding Commercial Momentum - insights.citeline.com
How To Trade (VIR) - news.stocktradersdaily.com
Vir announces 24-week post-end of treatment data for Hep B therapy - MSN
Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus - MSN
Vir Biotechnology (VIR) Maintains 'Buy' Rating as Price Target A - GuruFocus
Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference - BioSpace
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Vir Biotechnology Announces Results of Its Potential Hepatitis B Cure Combination Therapy - ContagionLive
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts - simplywall.st
Vir Biotechnology First Quarter 2025 Earnings: Revenues Disappoint - Yahoo Finance
Vir Biotechnology (VIR) Unveils Promising Hepatitis B Treatment Data | VIR Stock News - GuruFocus
Vir Biotechnology Announces Preliminary 24-Week Post-End of Trea - GuruFocus
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study - BioSpace
Vir Biotechnology (VIR) Reveals Promising Data in Hepatitis B Tr - GuruFocus
Vir Biotechnology (VIR) Reveals Promising Data in Hepatitis B Treatment - GuruFocus
Vir Biotechnology Presents Promising Phase 2 Hepatitis B Data - TipRanks
Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2025 Earnings Call Transcript - Insider Monkey
Vir posts mid-stage trial data for Hep B drug (VIR:NASDAQ) - Seeking Alpha
Vir Biotechnology’s Earnings Call: Mixed Sentiment Amid Progress - TipRanks
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | VIR Stock News - GuruFocus
Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment - Seeking Alpha
Vir Biotechnology Reports Q1 2025 Financial Results - TipRanks
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):